摘要
目的分析^(131)I治疗分化型甲状腺癌(DTC)合并远处转移患者的疗效和影响因素。方法152例DTC合并远端转移灶患者,经^(131)I清甲治疗后,133例患者接受了^(131)I阶段性长期治疗,平均剂量(172.3±22.4)mCi/次(1mCi=37MBq),^(131)I人均治疗(8.31±5.2)次,间隔(127±26)d,其余因转移灶不摄取^(131)I或其他并发症放弃^(131)I治疗。随访期1~10年。结果经^(131)I治疗后,37例(24.3%)治愈,82例病情好转或控制,总有效率为78.2%,其余无效或恶化。影响^(131)I疗效的主要因素包括转移灶的性质和部位、患者的年龄和^(131)I治疗的副反应。结论^(131)I是治疗DTC合并远处转移的有效手段,早期发现转移灶及控制^(131)I治疗的副反应是该治疗方法的关键。
Objective To investigate the therapeutic effect and analyze influencing factors in ^131I treated differentiated thyroid cancers (DTC) patients with remote metastases. Methods Of all 152 DTC patients after ^131I ablation therapy, 133 patients received long-term periodic ^131I treatment, with averaged doses of ( 172.3 ± 22.4) mCi per treatment 8.31±5.2 treatment per cases and averaged time intervals ( 127 ± 26) d (1 mCi = 37 MBq). Others were excluded from further ^131I therapy due to absence of ^131I uptake by the metastases or complications. The follow-up time ranged from 1 to 10 years. Results After ^131I treatments, 37 patients (24.3%) was completely cured and 82 patients improved or controlled, the overall effective rate reached 78.2%. Major factors affecting the treatment outcomes consisted of the characteristics and locations of the metastases, patients' age and their adverse reactions due to ^131I therapy. Conclusion ^131I is an effective method for the treatment of DTC patients with remote metastases. The key issues rely on the early detection of metastases and good management of adverse reactions.
出处
《上海第二医科大学学报》
CSCD
北大核心
2005年第12期1263-1266,共4页
Acta Universitatis Medicinalis Secondae Shanghai